fda compounding semaglutide warning november 2025 The Risks of Compounded Products FDA alerts health care providers,

What is Fatty Liver Disease

Getting a weight-loss prescription is easier said than done

ClinicalTrials+1 If these trials succeed, we may see GLP-1 drugs formally approved for brain-health or dementia-prevention in the coming years

In the newsroom, were taking a cl

The new Wegovy subscription program with Novo Nordisk is a sign that branded manufacturers want tighter control over: pricing distribution adherence patient experience Translation: the manufacturers (and soon other parties) are building the relationship layer that telehealth platforms assumed was theirs

Real-world data from the Dasman Diabetes Institute in Kuwait published in Diabetes, Obesity and Metabolism examined changes in body weight, HbA1c and other cardiometabolic factors for adults with overweight and